Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Preliminary Q3 Revenues Up 57 Percent

NEW YORK – Transplant diagnostics company CareDx said on Wednesday after the close of the market that its preliminary third quarter revenues rose an estimated 57 percent year over year.

For the three months ended Sept. 30, revenues are expected to be approximately $53 million, up from $33.8 million in Q3 2019. Analysts are expecting revenues of $44.7 million for the quarter.

Testing revenues for the quarter are expected to be approximately $45.2 million, up from $28.2 million in the year-ago period. CareDx said it returned approximately 21,800 total AlloSure and AlloMap patient results during the quarter. Product revenues are expected to be $5.4 million, up from $4.2 million in Q3 2019. Digital & other revenues are expected to be $2.4 million, compared to $1.4 million in the year-ago quarter.

"Our strong third quarter performance was driven by this dedication and our commitment to lead in advancing transplantation, underscored by our surveillance solutions, AlloSure and AlloMap," CareDx Chairman and CEO Peter Maag said in a statement.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.